NEWRON PHARMACEUTICALS SPA (NP5.DE) Stock Income Statement
Europe - FRA:NP5 - IT0004147952 - Common Stock
11.12 EUR
+0.06 (+0.54%)
| 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 51.39M | 9.06M | 6.09M | 5.76M | 5.26M | |||
| Cost Of Goods | 892.00K | 471.00K | 443.00K | 117.00K | 295.00K | |||
| Gross Profit | 50.50M | 8.59M | 5.65M | 5.64M | 4.96M | |||
| Operating Expenses | 24.32M | 20.21M | 18.95M | 18.00M | 23.03M | |||
| Research and Development | 12.68M | 12.61M | 11.49M | 10.55M | 15.90M | |||
| Selling, General, and Administrative Expenses | 11.45M | 7.40M | 7.26M | 7.25M | 8.32M | |||
| Operating Income | 26.17M | -11.63M | -13.30M | -12.36M | -18.07M | |||
| Interest Income/Expense | -4.31M | -4.06M | -3.77M | -2.66M | -2.35M | |||
| Other Income/Expense | -468.00K | -512.00K | -400.00K | 134.00K | 795.00K | |||
| Non Recurring Items | N/A | N/A | N/A | N/A | N/A | |||
| Income Before Taxes | 21.39M | -16.20M | -17.47M | -14.88M | -19.62M | |||
| Income Tax | 5.55M | 24.00K | 21.00K | 17.00K | 1.38M | |||
| Net Income | 15.84M | -16.22M | -17.49M | -14.90M | -21.00M | |||
| EBITDA | 26.36M | -11.43M | -13.10M | -12.15M | -17.85M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | 0.85 | -0.91 | -0.98 | -0.83 | -1.18 | |||
| Non GAAP EPS | 0.85 | -0.91 | -0.98 | -0.84 | -1.18 | |||
| Statistics | ||||||||
| Gross Profit Margin | 98.26% | 94.80% | 92.73% | 97.97% | 94.39% | |||
| Profit Margin | 30.83% | -179.13% | -287.05% | -258.61% | -399.35% | |||
| Operating Profit Margin | 50.93% | -128.40% | -218.28% | -214.46% | -343.59% | |||
All data in EUR